AAAAAA
Results: 1-25/26
Authors:
Drummond, M
Citation: M. Drummond, The end of software as we know it, FORTUNE, 144(10), 2002, pp. 52
Authors:
Trueman, P
Drummond, M
Hutton, J
Citation: P. Trueman et al., Developing guidance for budget impact analysis, PHARMACOECO, 19(6), 2001, pp. 609-621
Authors:
Sculpher, M
Drummond, M
O'Brien, B
Citation: M. Sculpher et al., Effectiveness, efficiency, and NICE - A NICE start but evidence costs money, BR MED J, 322(7292), 2001, pp. 943-944
Authors:
Martinez-Argudo, I
Martin-Nieto, J
Salinas, P
Maldonado, R
Drummond, M
Contreras, A
Citation: I. Martinez-argudo et al., Two-hybrid analysis of domain interactions involving NtrB and NtrC two-component regulators, MOL MICROB, 40(1), 2001, pp. 169-178
Authors:
Shannon, C
Crombie, C
Brooks, A
Lau, H
Drummond, M
Gurney, H
Citation: C. Shannon et al., Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: Effective treatment of patients with poor prognostic features, ANN ONCOL, 12(7), 2001, pp. 947-952
Authors:
Drummond, M
Citation: M. Drummond, Introducing economic and quality of life measurements into clinical studies, ANN MED, 33(5), 2001, pp. 344-349
Authors:
Coyle, D
Welch, V
Shea, B
Gabriel, S
Drummond, M
Tugwell, P
Citation: D. Coyle et al., Issues of consensus and debate for economic evaluation in rheumatology, J RHEUMATOL, 28(3), 2001, pp. 642-647
Authors:
Gabriel, S
Drummond, M
Coyle, D
Suarez-Almazor, ME
Ruff, B
Guillemin, F
Bombardier, C
Boers, M
Maetzel, A
Ruof, J
Cranney, A
Marentette, M
Tugwell, P
Citation: S. Gabriel et al., OMERACT 5 Economics Working Group: Summary, recommendations, and research agenda, J RHEUMATOL, 28(3), 2001, pp. 670-673
Authors:
Colnaghi, R
Cassinelli, G
Drummond, M
Forlani, F
Pagani, S
Citation: R. Colnaghi et al., Properties of the Escherichia coli rhodanese-like protein SseA: contribution of the active-site residue Ser240 to sulfur donor recognition, FEBS LETTER, 500(3), 2001, pp. 153-156
Authors:
Sculpher, MJ
Poole, L
Cleland, J
Drummond, M
Armstrong, PW
Horowitz, JD
Massie, BM
Poole-Wilson, PA
Ryden, L
Citation: Mj. Sculpher et al., Low doses vs. high doses of the angiotensin converting-enzyme inhibitor lisinopril in chronic heart failure: a cost-effectiveness analysis based on the Assessment of Treatment with Lisinopril and Survival (ATLAS) study, EUR J HE FA, 2(4), 2000, pp. 447-454
Authors:
Nixon, J
Stoykova, B
Christie, J
Glanville, J
Kleijnen, J
Drummond, M
Citation: J. Nixon et al., NHS Economic Evaluation Database for healthcare decision makers, BR MED J, 321(7252), 2000, pp. 32-32
Authors:
Drummond, M
Citation: M. Drummond, Conference costs, PSYCHOLOGIS, 13(8), 2000, pp. 392-393
Authors:
Stoykova, B
Glanville, J
Christie, J
Drummond, M
Kleijnen, J
Citation: B. Stoykova et al., The UKNHS Economic Evaluation Database - Economic issues in evaluations ofhealth technology, INT J TE A, 16(3), 2000, pp. 731-742
Authors:
Drummond, M
Weatherly, H
Citation: M. Drummond et H. Weatherly, Implementing the findings of health technology assessments - If the CAT got out of the bag, can the TAIL wag the dog?, INT J TE A, 16(1), 2000, pp. 1-12
Authors:
Davies, L
Drummond, M
Papanikolaou, P
Citation: L. Davies et al., Prioritizing investments in health technology assessment - Can we assess potential value for money?, INT J TE A, 16(1), 2000, pp. 73-91
Authors:
Zappa, S
Drummond, M
Harrington, R
Walker, C
Bradley, L
Citation: S. Zappa et al., Susan Fuller: LJ hero, LIBRARY J, 124(9), 1999, pp. 8-8
Authors:
Gabriel, S
Tugwell, P
O'Brien, B
Yelin, E
Drummond, M
Ruff, B
Brooks, P
Bombardier, C
Boers, M
Citation: S. Gabriel et al., Report of the OMERACT task force on economic evaluation, J RHEUMATOL, 26(1), 1999, pp. 203-206
Authors:
Drummond, M
Stamper, J
Citation: M. Drummond et J. Stamper, DNAPROBE, a computer program which generates oligonucleotide probes from protein alignments, NUCL ACID R, 27(17), 1999, pp. 3493-3493
Authors:
Freemantle, N
Eccles, M
Wood, J
Mason, J
Nazareth, I
Duggan, C
Young, P
Haines, A
Drummond, M
Russell, I
Walley, T
Citation: N. Freemantle et al., A randomized trial of Evidence-based OutReach (EBOR): Rationale and design, CONTR CL TR, 20(5), 1999, pp. 479-492
Authors:
Mason, A
Drummond, M
Towse, A
Citation: A. Mason et al., Is disease management relevant in Europe: some evidence from the United Kingdom, HEALTH POLI, 48(1), 1999, pp. 69-77
Authors:
Mason, FNMJ
Eccles, M
Freemantle, N
Drummond, M
Citation: Fnmj. Mason et al., A framework for incorporating cost-effectiveness in evidence-based clinical practice guidelines, HEALTH POLI, 47(1), 1999, pp. 37-52
Authors:
Brewin, B
Woodley, P
Drummond, M
Citation: B. Brewin et al., The basis of ammonium release in nifL mutants of Azotobacter vinelandii, J BACT, 181(23), 1999, pp. 7356-7362
Authors:
Souza, EM
Pedrosa, FO
Drummond, M
Rigo, LU
Yates, MG
Citation: Em. Souza et al., Control of Herbaspirillum seropedicae NifA activity by ammonium ions and oxygen, J BACT, 181(2), 1999, pp. 681-684
Authors:
Aslan, P
Brooks, A
Drummond, M
Woo, H
Citation: P. Aslan et al., Incidence and management of gynaecological-related ureteric injuries, AUST NZ J O, 39(2), 1999, pp. 178-181
Authors:
Thompson, S
Drummond, M
Citation: S. Thompson et M. Drummond, Health economic and health benefit issues in endocrine trials, ENDOCR DEV, 1, 1999, pp. 33-54